Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines.
Simone Rossi, Andrea Antal, Sven Bestmann...
https://pubmed.ncbi.nlm.nih.gov/33243615/Actively Recruiting
Led by Medical College of Wisconsin · Updated on 2026-07-13
135
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the effects of transcranial magnetic stimulation TMS on brain structure and specific language functions in people with stroke and aphasia, as well as healthy individuals. This study aims to understand how short-term changes affect semantic and phonological language processes and their interaction with other cognitive areas that influence language. The brain targets for TMS are chosen based on prior studies using neuroimaging and neuropsychological methods. The study uses the Deymed DuoMag XT-100 rTMS system with a 70-mm figure-of-eight coil to deliver active repetitive or rapid TMS to targeted brain sites, control sites, or sham conditions. Participants receive TMS either at the language-related brain regions or control areas, allowing comparison of effects. The study design is within-subject, randomized, and double-blinded, involving healthy individuals and stroke survivors with aphasia. Participants will perform language tasks immediately before and after TMS administration on the same day to measure reaction time and accuracy. These assessments help evaluate the impact of TMS on language processing. The study lasts until June 2032 and includes safety monitoring to ensure participant well-being during TMS sessions.
CONDITIONS
Language Processing and TMS
S
Sidney Schoenrock
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Medical College of Wisconsin
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Active TMS | Control TMS | Sham TMS |
|---|---|---|---|
| What it is | Active repetitive transcranial magnetic stimulation (rTMS) applied using the Deymed DuoMag XT-100 device. | Alternative TMS protocol applied as a control intervention. | Sham TMS procedure simulates device use without active stimulation. |
| Role in trial | Tests whether active TMS improves language task performance after stroke. | Provides a comparison for device and protocol effect on language tasks. | Acts as a placebo comparator to distinguish true device impact from expectation. |
| Primary use | Investigational use for potential improvement of aphasia and language processing after stroke. | Comparator device protocol for measuring TMS effects on language functions. | Placebo comparison for assessing the influence of expectation or device experience. |
| How it is given or performed | Participants receive active rTMS with protocol parameters set to the device specification. Sessions target left hemisphere post-stroke regions. | Participants undergo a control TMS protocol with device settings designed for comparison but not for active stimulation. | Participants undergo sham stimulation mimicking device activity without true magnetic pulses. |
| Evidence status | Active TMS for post-stroke aphasia remains investigational; limited evidence exists and results from this trial are not yet established. | Control TMS protocol is investigational; evidence regarding comparative effect is pending trial outcomes. | Sham TMS serves as a comparator; no clinical outcome evidence exists as it does not deliver active stimulation. |
| Important limitations | Safety for TMS in post-stroke aphasia is still under investigation. Seizure risk, careful screening, and ethical safeguards apply, as noted by expert guidelines. | Control protocol limitations include uncertainty about device settings and potential lack of therapeutic effect; safety screening remains important. | Sham TMS does not produce clinical effects but must adequately mimic device experience to maintain blinding; patient risk is minimal, but ethical challenges exist. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Varies by participant
Participants receive active, control, or sham repetitive or rapid TMS using the Deymed DuoMag XT-100 device targeting specific brain areas related to language processing.
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Simone Rossi, Andrea Antal, Sven Bestmann...
https://pubmed.ncbi.nlm.nih.gov/33243615/Shalini Narayana, Savannah K Gibbs, Stephen P Fulton...
https://pubmed.ncbi.nlm.nih.gov/34093397/R Chen, J Classen, C Gerloff...
https://pubmed.ncbi.nlm.nih.gov/9153480/Lindsay Oberman, Dylan Edwards, Mark Eldaief...
https://pubmed.ncbi.nlm.nih.gov/21221011/P M Rossini, S Rossi
https://pubmed.ncbi.nlm.nih.gov/9743275/J C Keel, M J Smith, E M Wassermann
https://pubmed.ncbi.nlm.nih.gov/11332408/Mark Hallett
https://pubmed.ncbi.nlm.nih.gov/17640522/Roy H Hamilton, Evangelia G Chrysikou, Branch Coslett
https://pubmed.ncbi.nlm.nih.gov/21459427/V Walsh, A Cowey
https://pubmed.ncbi.nlm.nih.gov/11252771/Ying-Zu Huang, Mark J Edwards, Elisabeth Rounis...
https://pubmed.ncbi.nlm.nih.gov/15664172/Medical College of Wisconsin
Lead Sponsor